Dianthus Therapeutics
DNTH
70 hedge funds and large institutions have $419M invested in Dianthus Therapeutics in 2019 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 25 increasing their positions, 10 reducing their positions, and 8 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 10
113% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 8
11% more funds holding
Funds holding: 63 → 70 (+7)
3% more capital invested
Capital invested by funds: $406M → $419M (+$12.6M)
1.52% less ownership
Funds ownership: 73.94% → 72.42% (-1.5%)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$36.2M |
| 2 |
BlackRock
New York
|
+$7.54M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$6.57M |
| 4 |
Alkeon Capital Management
New York
|
+$6.18M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$21M |
| 2 |
AG
Artal Group
Luxembourg
|
-$2.73M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$880K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$691K |
| 5 |
SIM
Spark Investment Management
New York
|
-$408K |
DNTH Hedge Fund Activity: Q2 2019 in Review
70 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q2 2019, worth a combined $419M — up 3.1% from $406M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new DNTH positions and 8 closed out — a net gain of 9 holders — while 25 added to existing stakes and 10 trimmed.
The largest buyer was Gilder Gagnon Howe & Co, adding an estimated $36.2M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $21M sold.
- 70 institutional investors held Dianthus Therapeutics (DNTH) as of Q2 2019, up from 63 in Q1 2019.
- Funds reported $419M of Dianthus Therapeutics stock for Q2 2019, up 3.1% quarter-over-quarter.
- 17 funds opened new Dianthus Therapeutics positions in Q2 2019 and 8 closed out, a net change of +9 holders.
- The largest Dianthus Therapeutics buyer in Q2 2019 was Gilder Gagnon Howe & Co, an estimated $36.2M added.
- The largest Dianthus Therapeutics seller in Q2 2019 was EcoR1 Capital, an estimated $21M sold.
Based on aggregated 13F filings for Q2 2019.